The October 2026 CHMP meeting recommended five extensions of indication, including for Talvey, Tryngolza, Tukysa, Kyinsu and a pandemic influenza H5N1 vaccine. EMA counts 97 such positive opinions so far this year. Extensions are a central lifecycle lever.
How an extension works
A new indication for an authorised centrally authorised product is submitted as an extension application, a type of Type II variation. It is assessed on the clinical evidence, the proposed wording of the indication and the effect on the benefit-risk balance, and results in updated product information.
The extra year of market protection
Under the current framework, a marketing authorisation holder can obtain one additional year of market protection if, during the first eight years, a new indication is authorised that brings significant clinical benefit compared with existing therapies. This can extend the protection period from ten to eleven years. Eligibility is assessed at the time of the application, so planning must start early.
What drives success
- Evidence that supports the specific wording. Subgroups and biomarker definitions should match pivotal data.
- Comparator choice. Significant clinical benefit is judged against existing options.
- Consistent labelling. Sections 4.1, 4.2 and 5.1 must align.
After the opinion
An extension changes the commercial and access picture. National reimbursement may need to be renewed or expanded for the new indication, and risk management and pharmacovigilance plans should be updated.
How PQRA helps
PQRA supports variation strategy, extension dossiers and the follow-through into Greek reimbursement submissions, so each new indication is exploited fully.


No responses yet